Colorectal Cancer Clinical Trial
Official title:
Feasibility Study of Preoperative Exercise Intervention in the Resection of Colorectal Liver Metastasis.
Each year in the UK around 1500 patients undergo surgery for bowel cancer that has spread to
the liver. This is major surgery that offers a chance of cure, but can be associated with
complications. Fitter patients are less likely to have serious complications. We are
interested in finding out whether a short exercise program can improve patient fitness
before surgery and whether this can reduce surgical complications.
We plan to measure the fitness of patients who are going to have liver surgery. We will then
give them an exercise programme for 4 weeks, after which we will assess their fitness again.
We are also interested in whether fitter people have better Liver function. To assess this
we will take a small sample of liver tissue during the operation for laboratory analysis of
its function.
Hypothesis
1. A short period of exercise can significantly improve fitness prior to liver surgery
2. Greater Fitness is associated with better liver function.
Prehabilitation in Liver Surgery
Introduction Thirty per cent of patients with colorectal cancer have metastatic disease at
time of presentation, and a further 20% will develop liver metastases after the primary
colorectal malignancy has been resected. Liver resection offers the prospect of cure for a
proportion of these patients and, with the increasing use of effective neo-adjuvant
chemotherapy, this proportion is increasing. However, liver surgery is associated with
significant morbidity and mortality and this may be higher in patients with comorbidity,
poor cardiorespiratory fitness and in those who have received neo-adjuvant chemotherapy.
Cardiopulmonary exercise testing (CPET) is a non-invasive assessment of cardiovascular and
pulmonary function, which can be quantified by measures such as anaerobic threshold (AT) and
VO2peak. The anaerobic threshold is a measure of sustainable exercise, where the VO2peak is
a measure of maximal exercise capacity. The AT has been assessed in different surgical
groups and has been shown as a useful predictor of postoperative complications and survival.
Early work has demonstrated that short periods of preoperative exercise intervention can
improve AT and VO2peak. However, no work has to date been undertaken in patients prior to
liver surgery.
Hepatic glucose metabolism provides much of the energy requirements of the postoperative
period. Work has demonstrated that exercise training increases hepatic glucose production,
and that its inhibition has a marked effect on endurance capability. This may be
particularly relevant when surgical resections can involve resection of up to 80% of hepatic
tissue. However, a link between hepatic gluconeogenic capacity and fitness as assessed by
cardiopulmonary exercise testing has not been established.
A demonstrable link between gluconeogenic capacity and cardiopulmonary fitness and an
explanation of its underpinning physiology would help explain some of the systemic effects
of drug hepatotoxicity. It would also allow development of strategies to improve
gluconeogenic capacity that may reduce complications and improve tolerance of many hepatoxic
agents such as chemotherapy.
Hypothesis
1. A short exercise program can significantly improve the CPET defined anaerobic threshold
prior to liver surgery in a cancer population and this will be associated with reduced
post-operative morbidity and mortality.
2. Hepatic gluconeogenic capacity will be associated with cardiopulmonary fitness.
3. Gluconeogenic capacity will be associated with mitochondrial number and quantity of
enzymes which are integral to gluconeogenesis such as PEPCK
Methods Patients with colorectal liver metastases suitable for hepatic resection will
undergo a baseline CPET and then be randomised to either preoperative exercise intervention
or standard care. Patients within the intervention arm will undergo a 4 week exercise
program consisting of 3 interval sessions per week on a stationary bike. This will be
individually tailored according to their initial exercise test. In the week prior to surgery
all patients will then undergo a further CPET. At surgery liver tissue will be taken to
determine hepatic gluconeogenic capacity. CPET tests will then be performed where possible
in patients at 6 weeks and 3 months following surgery. Post-operative complications (Clavien
classification and Postoperative morbidity score (POMS)) and 30 and 90-day mortality will be
recorded. Quality of life assessments (EORTC/SF-36) will be taken at recruitment, the week
prior to surgery, 6 weeks after surgery and 3 months following surgery.
Laboratory Analysis Hepatic gluconeogenic capacity will be assessed by direct analysis of
fresh slices of hepatic tissue taken at the time of surgery. Slices will be taken using the
Krumdiek MD6000 tissue slicer. These will be weighed an incubated in a buffer containing
lactate. Glucose will be measured using the Glucose Oxidase assay, and calculated per mg wet
weight of hepatic tissue. Further analysis of mitochondrial number and ATP production, and
enzymatic levels will be conducted following initial results.
Statistical considerations This is a study of a continuous response variable from matched
pairs of study subjects and will need 38 patients to detect a true difference 1.5ml/min/kg,
with a probability 0.8 and Type I error 0.05). Anticipated recruitment period is 10 months
assuming a dropout rate of 20%. Randomisation is by computerised block randomisation, and
patients will be stratified by receipt of neo-adjuvant chemotherapy.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |